Critical Care Department, Hospital Universitario Dr. Peset, Valencia, Spain.
Fundación Micellium, Valencia, Spain.
Crit Care. 2020 Jun 29;24(1):383. doi: 10.1186/s13054-020-03091-2.
In accordance with the recommendations of, amongst others, the Surviving Sepsis Campaign and the recently published European treatment guidelines for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), in the event of a patient with such infections, empirical antibiotic treatment must be appropriate and administered as early as possible. The aim of this manuscript is to update treatment protocols by reviewing recently published studies on the treatment of nosocomial pneumonia in the critically ill patients that require invasive respiratory support and patients with HAP from hospital wards that require invasive mechanical ventilation. An interdisciplinary group of experts, comprising specialists in anaesthesia and resuscitation and in intensive care medicine, updated the epidemiology and antimicrobial resistance and established clinical management priorities based on patients' risk factors. Implementation of rapid diagnostic microbiological techniques available and the new antibiotics recently added to the therapeutic arsenal has been reviewed and updated. After analysis of the categories outlined, some recommendations were suggested, and an algorithm to update empirical and targeted treatment in critically ill patients has also been designed. These aspects are key to improve VAP outcomes because of the severity of patients and possible acquisition of multidrug-resistant organisms (MDROs).
根据《拯救脓毒症运动》和最近发布的欧洲医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)治疗指南的建议,如果患者发生此类感染,经验性抗生素治疗必须是合适的,并尽早进行。本文的目的是通过回顾最近发表的关于需要侵入性呼吸支持的危重症患者和需要侵入性机械通气的医院病房 HAP 患者的医院获得性肺炎治疗的研究,更新治疗方案。一个由麻醉和复苏以及重症医学专家组成的跨学科专家组,根据患者的危险因素更新了流行病学和抗菌药物耐药性,并确定了临床管理重点。已经审查和更新了快速诊断微生物学技术的应用和最近添加到治疗武器库中的新抗生素。在分析了列出的类别后,提出了一些建议,并设计了一个针对危重症患者进行经验性和靶向治疗的更新算法。由于患者的严重程度和可能获得多药耐药菌(MDROs),这些方面是改善 VAP 结果的关键。